Why use EDC if eSource has the endpoint data? In the CRIO article, Automate the protocol with eSource, we described how CRIO eSource automates the protocol, building compliance at the point of capture. CRIO is often asked if we can send the data to the EDC. The answer is yes, if the EDC system’s API...
CRIO’s integrated eSource-EDC model revolutionizes both the data entry process at the site level and the monitoring process from the CRO perspective. According to a third party survey of CRAs who have used CRIO, CRAs agreed by a margin of 23:1 that this new model would increase overall trial efficiency, improve data quality, and enhance...
Overview This past April, the FDA released updated guidance to sponsors and pharmaceutical companies on increasing racial and ethnic diversity in clinical trials to propel more inclusive research. Racial and ethnic minorities have historically been underrepresented in research,1 even within diseases where they make up the majority of those affected. The FDA also advises sponsors...
Over 13,000 protocols have gone through the CRIO system, and in the vast majority of them, CRAs have used CRIO to monitor source. We’ve always heard from our sites that their CRAs love the system, but now we have proof. According to a third party survey of CRAs who have used CRIO, by a healthy...
While bugs are as natural in coding as they are in nature, we don’t want them creeping into our code. At CRIO, we have established various processes and procedures to handle bugs. At the close of 2022, we hosted a Bugathon, part of our ongoing efforts to deliver best-in-class quality. The Bugathon was a two...
Overview With 9 locations in Texas, California and Louisiana, Benchmark Research is the world’s leading vaccine network. Benchmark has performed over 10,000 studies on over 40,000 subjects and has received numerous awards, including being a five-time recipient of the Best Clinical Trial Site/Network award from the World Vaccine Congress. Challenge Historically, Benchmark used paper charts...
BOSTON, MA – November 3, 2022 – CRIO, the industry’s leading eSource provider, announces the appointment of Dr. Margaretta Nyilas to its Board of Directors, effective immediately. Dr. Nyilas is a biopharmaceutical executive with over twenty years of diverse global industry experience, formerly at Otsuka Pharmaceuticals, Bristol Myers Squibb and Click Therapeutics. She has a...
With the recent push toward Decentralized Clinical Trials (DCTs), many sponsors are adopting eConsent. eConsent allows patients to consent electronically, whether in clinic or remotely, from the convenience of their home. eConsent offers sponsors, CROs, investigators and patients these benefits: Reduce errors by ensuring completion of all fields Automated audit trails ensure accuracy of date-times...
Mary Brenner, MSN MArch RN, is CRIO’s Study Design Manager and brings deep-rooted expertise as a registered nurse to CRIO’s in-house study design team. In this quick Q&A, Mary shares the benefits of good study design for sponsors and sites, the downstream effects of standardized study designs, and gives tips for designing it on your...
BOSTON, MA – August 9, 2022 – CRIO, a Boston-based healthcare technology company streamlining clinical trials for sponsors, sites and patients, announced that it has reached another milestone, exceeding 2,000 clinical research sites standardizing on CRIO’s eSource platform. CRIO supports a variety of clinical trial data. To date, over 800 life science sponsors have data...
73% of sites reported using paper as the primary means of data collection In a 2018 CRIO site survey with over 100 respondents, sites reported that they use their Electronic Medical Record (EMR) primarily for patient recruitment purposes, but not for source data collection. 62% of site respondents reported that they use the EMR as...
For every clinical trial, the sponsor and/or a CRO will conduct a site selection process to determine what research sites are suitable to conduct their trial. A site’s ‘suitability’ is measured by a multitude of factors including but not limited to previous experience conducting clinical trials, research experience for a specific indication, resources available at...
